Inventiva S.A. (IVA), a France-based clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its focus on developing innovative treatments for metabolic and fibrotic diseases. As it stands, the company has a market capitalization of $1.39 billion, and its stock, priced currently at $6.70, has shown a promising trajectory within its 52-week range of $2.74 to $7.15. With a notable potential upside of 131.10%, investors are keenly watching this healthcare player.

Inventiva’s flagship drug candidate, Lanifibranor, is currently in a Phase 3 clinical trial (NATiV3) targeting metabolic dysfunction-associated steatohepatitis (MASH), a condition with significant unmet medical needs globally. Another…